Summary
Follow-up studies were conducted in the patients with chronic active hepatitis treated 10 years ago with tiopronin (TP) or corticosteroids (CS). HB surface antigen (HBsAg) was measured in previously collected paraffin embedded liver sections by enzyme-labelled antibody technique. Of 72 cases examined, 15 cases were treated with TP only (8 cases) and combination with CS (7 cases), 38 cases with CS and 19 cases not treated with TP or CS (control group). Two deaths occurred in TP group (each 1 case in the single and combination treatments) in the 9th year due to bleeding of oesophageal varices in a chronic aggressive hepatitis (2B type) with HBsAg diffusely distributed in liver tissue. Two deaths were found in CS group and 4 in the control group. No significant difference was noted in the rehabilitation rate in HBsAg negative cases of TP group and CS group versus the control group. In the positive cases, the rehabilitation rate was found to be 66.7% in the CS group compared with 0% in the non-CS group, and each 3 cases out of 5 rehabilitated by the single and combination treatments with TP respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tsuji T, Tokuyama K, Naito K, Okazaki S, Shinohara T, Araki K, Okada T, Nozaki H, Nagashima H: A case report of primary hepatic carcinoma with prolonged HB virus infection and monoclonal gammopathy. Gastroenterol Jpn 12: 69–75, 1977.
Ohta Y, Tsuji T, Nozaki H: Corticosteroid therapy in chronic hepatitis. Its reevaluation. Clin Immunol 7: 1145–1155, 1975 (Jpn)
Ohta Y, Tsuji T, Yoshida T, Yamada G, Kosaka K: Depolymerization of immunoglobulin M by α-mercaptopropionylglycine (Thiola) and its relation to rheumatoid factor in chronic liver diseases. Proceedings of the International Symposium on Thiola, Nov 25–26, 1970, Tokyo; 132–140
Kosaka K, Ohta Y, Tsuji T: A therapeutic effect of 2-mercaptopropionylglycine (MPG) on Australia antigen positive hepatitis. Proceedings of the Second International Symposium on Thiola, Dec 29–30, 1972, Jamaica; 79–88
Tsuji T, Naito K, Tokuyama K, Okada T, Kosaka K: Detection of HBs antigen in routine paraffin embedded liver tissue by enzyme-labelled antibody technique. Acta Med Okayama 30: 69–73, 1976
De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uhlinger E, Wepler W: A classification of chronic hepatitis. Lancet 2: 626–628, 1968
Tsuji T, Naito K, Tokuyama K, Okada T, Takata S, Araki K, Shinohara T, Inoue J, Onoue K, Tsuchiya M, Nozaki H, Nagashima H, Hayama K: Follow-up ten years after corticosteroid therapy for chronic active hepatitis type B. Hepato-Gastroenterology 27: 85–90, 1980
Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Human Pathol 4: 183–198, 1972
Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisolone and azathioprine in active chronic hepatitis. Lancet 1: 735–737, 1973
Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biological, and histological remission of severe chronic active liver disease. A controlled study of treatments and early prognosis. Gastroenterology 63: 820–833, 1972
Whelan G, Sherlock S: Immunosuppressive activity in patients with active chronic hepatitis and primary biliary cirrhosis treated with azathioprine. Gut 13: 907–914, 1972
Cook GC, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Quart J Med 40: 159–185, 1971
Geal MG, Schoenfield LJ, Summerskill WHJ: Classification and treatment of chronic active liver disease. Gastroenterology 55: 724–729, 1968
Summerskill WHJ, Ammon HV, Baggenstoss AH: Treatment of chronic hepatitis, In: The Liver and Its Diseases: ed by T Schaffner, S Scherlock, CM Leevy, International Medical Book Corporation, New York, 216–226, 1973
Ohta Y, Tsuji T: Immunosuppressive therapy on chronic liver diseases. Autoimmune phenomena and effects of immunosuppressive drugs in progress of chronic hepatitis. Clin Immunol 2: 55–70, 1970 (Jpn)
Author information
Authors and Affiliations
Additional information
This work was supported by a Grant from the Ministry of Health & Welfare, and the grant (No. 56570285) of the Ministry of Education of Japan.
Rights and permissions
About this article
Cite this article
Tsuji, T., Nagashima, H. Follow-up study in chronic active hepatitis after therapies with immunosuppressive drugs and tiopronin. Gastroenterol Jpn 16, 568–575 (1981). https://doi.org/10.1007/BF02813791
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02813791